Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Loss of STAG2 Gene Improves Bladder Cancer Prognosis

By BiotechDaily International staff writers
Posted on 23 Oct 2013
Image: This image shows a bladder tumor sample containing mutations in the STAG2 gene (Photo courtesy of the Spanish National Cancer Research Center).
Image: This image shows a bladder tumor sample containing mutations in the STAG2 gene (Photo courtesy of the Spanish National Cancer Research Center).
Results obtained during a study conducted by Spanish cancer researchers indicated that mutations of the STAG2 (stromal antigen 2) gene suppressed development of urothelial bladder cancer (UBC) by acting through mechanisms that were different from the gene's role in preventing aneuploidy.

The protein encoded by the STAG2 gene is a subunit of the cohesin complex, which regulates the separation of sister chromatids during cell division. Targeted inactivation of this gene results in chromatid cohesion defects and aneuploidy, suggesting that genetic disruption of cohesin is a cause of aneuploidy in human cancer.

Bladder cancer represents a serious public health problem in many countries, especially in Spain, where 11,200 new cases are recorded every year, one of the highest rates in the world. The majority of these tumors have a good prognosis for five-year survival after diagnosis, and most have not infiltrated the bladder muscle at the time of diagnosis.

Investigators at the Spanish National Cancer Research Center (Madrid) performed an exome sequencing study to identify genes linked to noninfiltrating bladder cancer. They analyzed the exome from 17 bladder cancer patients and subsequently validated the data by the analyzing a specific group of genes in 60 additional patients.

Results published in the October 13, 2013, online edition of the journal Nature Genetics revealed a set of previously unidentified genes mutated in these tumors coding for proteins involved in chromatin modification (MLL2, ASXL2, and BPTF), cell division (STAG2, SMC1A, and SMC1B) and DNA repair (ATM, ERCC2, and FANCA). STAG2 was significantly and commonly mutated or lost in UBC, mainly in tumors of low stage or grade, and its loss was associated with improved outcome.

Loss of STAG2 expression was often observed in chromosomally stable tumors, and STAG2 knockdown in bladder cancer cells did not increase aneuploidy. Insertion of STAG2 into nonexpressing cells led to reduced colony formation. Furthermore, analysis of bladder tumor tissue from more than 670 patients indicated that alterations in STAG2 were associated with a better prognosis.

"We found up to nine altered genes that had not been described before in this type of tumor, and of these we found that STAG2 was inactive in almost 40% of the least aggressive tumors," said senior author Dr. Francisco X. Real, head of the epithelial carcinogenesis group at the Spanish National Cancer Research Centre. "Some of these genes are involved in previously undescribed genetic pathways in bladder cancer, such as cell division and DNA repair; also, we confirmed and extended other genetic pathways that had previously been described in this cancer type, such as chromatin remodeling."

Related Links:

Spanish National Cancer Research Center



WATERS CORPORATION

Channels

Drug Discovery

view channel
Image: Star-like glial cells in red surround alpha-beta plaques in the cortex of a mouse with a model of Alzheimer\'s disease (Photo courtesy of Strittmatter laboratory/Yale University).

Experimental Cancer Drug Reverses Symptoms in Mouse Model of Alzheimer's Disease

An experimental, but clinically disappointing drug for treatment of cancer has been found to be extremely effective in reversing the symptoms of Alzheimer's disease (AD) in a mouse model.... Read more

Lab Technologies

view channel
Image: The gene assembly robot, the GeneTheatre (Photo courtesy of Analytik Jena AG).

Genomic Research Laboratories Await New Compact Liquid Handling System

A small footprint benchtop liquid handler that automates multiple gene assembly tasks and associated procedures such as PCR setup is now available for use by biotech and genomic research laboratories.... Read more

Business

view channel

NanoString and MD Anderson Collaborate on Development of Novel Multi-Omic Expression Profiling Assays for Cancer

The University of Texas MD Anderson Cancer Center (Houston, TX, USA) and NanoString Technologies, Inc. (Seattle, WA, USA) will partner on development of a revolutionary new type of assay—simultaneously profiling gene and protein expression, initially aiming to discover and validate biomarker signatures for immuno-oncology... Read more
 

Events

27 May 2015 - 28 May 2015
02 Jun 2015 - 03 Jun 2015
15 Jun 2015 - 18 Jun 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.